Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPECT ESUS: Dabigatran versus aspirin for secondary stroke prevention after embolic stroke of undetermined source
MOH_2017-05-09_000399Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in embolic stroke of undetermined source (ESUS) and ischemic stroke comparing Dabigatran etexilate plus placebo with Aspirin plus placebo (2 arms). Primary endpoint: Recurrent stroke. Started Mar 2016; status: recruiting.
02
Drugs
dabigatranaspirin
03
Conditions
embolic stroke of undetermined source (ESUS)ischemic stroke
Beyond the preview
Go deeper on MOH_2017-05-09_000399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-09_000399.